GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CG Oncology Inc.
Shares of CG Oncology, a biotech company developing drugs to treat bladder cancer, have soared following a successful IPO. The price reflects strong investor interest in its innovative approach and the potential of its lead drug to become a new standard of care.
Share prices of companies in the market segment - Cancer cure
CG Oncology is a biotech company developing drugs to treat bladder cancer. We classify it as part of the cancer treatment sector, and the chart below reflects the overall trends and the significant investor interest in this area of biotech.
Broad Market Index - GURU.Markets
CG Oncology is a biopharmaceutical company developing innovative immunotherapy for the treatment of bladder cancer. Its focus on oncology makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how CG Oncology is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
CGON - Daily change in the company's share price CG Oncology Inc.
For CG Oncology, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative oncology.
Daily change in the price of a set of shares in a market segment - Cancer cure
CG Oncology, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CGON's performance, which depends on the results of clinical trials of its cancer treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
CG Oncology is a biopharmaceutical company developing oncolytic immunotherapy for the treatment of cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating CG Oncology stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CG Oncology Inc.
CG Oncology has become a biotech star over the past year thanks to its success in developing bladder cancer therapies. Its year-over-year share price performance, shown in the chart, directly reflects breakthrough clinical data, which has been highly praised by investors.
Annual dynamics of market capitalization of the market segment - Cancer cure
CG Oncology, a recent and successful IPO, is a biotech company developing innovative immunotherapy for bladder cancer. Its impressive clinical data has attracted significant attention. The chart below shows how the market views its high growth potential compared to the broader biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CG Oncology is a biotech company whose future depends on the success of its innovative cancer treatments. Its stock price is completely disconnected from economic cycles. The chart reflects scientific events—news about clinical trials and regulatory decisions—rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CG Oncology Inc.
CG Oncology, a biotech company developing immunotherapy for bladder cancer, has sharp monthly fluctuations reflecting news about clinical trials of its lead drug, a key factor for companies at this stage.
Monthly dynamics of market capitalization of the market segment - Cancer cure
CG Oncology, Inc. is a biopharmaceutical company developing a new class of oncolytic immunotherapies for the treatment of bladder cancer. The dynamics of its sector, shown in the chart, reflect high risks. Against this backdrop, it is possible to assess how promising clinical trial results and the high demand for new treatments impact the company's prospects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CG Oncology is a biopharmaceutical company developing immunotherapy for bladder cancer. Oncology biotech stocks often live in a world of their own. The chart below shows how successful clinical trial data has allowed the company's shares to soar, defying any negative trends in the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CG Oncology Inc.
Shares of CG Oncology, a clinical-stage biotech, are extremely volatile. Weekly price movements are driven solely by news about the development of their cancer treatments. The chart below illustrates how investor expectations and scientific data can drive sharp short-term swings in the oncology sector.
Weekly dynamics of market capitalization of the market segment - Cancer cure
How unique is CG Oncology's performance in the biotech sector? This chart compares the company's weekly stock price movements, driven by news of its cancer clinical trials, with the overall trend. This helps us understand whether a sharp stock move is the result of a unique scientific breakthrough or a reflection of general sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CG Oncology is developing an innovative immunotherapy for bladder cancer. Like many biotechs, its stock is driven by expectations. This chart shows how out of sync its weekly performance is with the broader market. Price movements are driven by news about clinical trials, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
CGON - Market capitalization of the company CG Oncology Inc.
CG Oncology's market capitalization reflects investors' bets on its innovative approach to treating bladder cancer with oncolytic viruses. As a development-stage biotech, its market cap reflects hopes for clinical trial success rather than profits. The dynamics clearly illustrate the high risk and potential for a breakthrough in oncology.
CGON - Share of the company's market capitalization CG Oncology Inc. within the market segment - Cancer cure
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. Its market share in the oncology sector reflects the high potential of its immunotherapeutic approaches. The chart shows how investor expectations for its clinical developments shape its value and influence in the fight against this common cancer.
Market capitalization of the market segment - Cancer cure
The chart below shows the pulse of the biotech sector focused on immuno-oncology. CG Oncology is a prominent representative of the new generation of companies. The dynamics in the chart reflect the enormous investment and hopes associated with the search for innovative treatments for bladder cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new method to fight cancer. CG Oncology's market cap has skyrocketed thanks to investor faith in its innovative viral therapy. The line illustrates how a single breakthrough idea in oncology can quickly capture a significant share of the entire biotech sector's market cap.
Book value capitalization of the company, segment and market as a whole
CGON - Book value capitalization of the company CG Oncology Inc.
The chart below shows the financial foundation of CG Oncology, a clinical-stage biopharmaceutical company. The line represents the value of its intellectual property for cancer immunotherapy drugs and the funding for research. Growth on the chart signifies successful capital raising for the development of its core asset—science.
CGON - Share of the company's book capitalization CG Oncology Inc. within the market segment - Cancer cure
For CG Oncology, at the forefront of the fight against cancer, its tangible assets are not giant factories, but high-tech laboratories and clinical centers. The chart shows the company's share of the scientific infrastructure in its niche, which is the springboard for developing breakthrough cancer treatments.
Market segment balance sheet capitalization - Cancer cure
CG Oncology is a late-stage biotech company. Its value is created in laboratories where innovative cancer treatments are being developed. This is a "light" model. Is such a focus on R&D the norm for oncology? The chart below shows the total material "weight" of the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
CG Oncology's balance sheet isn't made up of factories, but rather capital, fully focused on the development and clinical trials of an innovative bladder cancer treatment. The book value chart shows the amount of financial resources devoted to fighting this specific type of cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CG Oncology Inc.
CG Oncology is a biotech company focused on developing viral therapy for bladder cancer. It has no tangible assets other than cash. Its market capitalization reflects investors' faith in its breakthrough technology and the clinical success of its lead drug. The chart reflects the high stakes and expectations associated with innovative oncology.
Market to book capitalization ratio in a market segment - Cancer cure
CG Oncology is a biotech company developing drugs to treat bladder cancer. The company has minimal tangible assets, and its market capitalization is based on the enormous expectations surrounding its lead drug. This chart demonstrates the investors' strong faith in its future commercial success.
Market to book capitalization ratio for the market as a whole
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. The chart clearly demonstrates the market's enormous anticipation of this potential breakthrough in oncology. Its market capitalization, which is many times greater than its book value, reflects investors' bet on the success of its clinical trials and the drug's future commercial potential.
Debts of the company, segment and market as a whole
CGON - Company debts CG Oncology Inc.
CG Oncology is a late-stage clinical development biopharmaceutical company focused on the treatment of bladder cancer. For such a company, debt is a strategic tool for funding the final stages of clinical trials and preparing for the commercial launch of its lead drug.
Market segment debts - Cancer cure
CG Oncology is a late-stage biopharmaceutical company developing innovative treatments for bladder cancer. Funding in biotech is critical for conducting expensive trials. This chart provides insight into the industry's financial norms, which CG Oncology is raising capital against to bring its drug to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CG Oncology Inc.
CG Oncology is a biotech company in late-stage clinical trials focused on developing treatments for bladder cancer. Funding late-stage research and preparing for commercialization requires significant resources. This chart shows how the company utilizes capital to achieve its goals.
Market segment debt to market segment book capitalization - Cancer cure
CG Oncology is a biopharmaceutical company at the forefront of the fight against bladder cancer, developing innovative immunotherapies. This chart compares its debt raised to fund clinical trials to the total market capitalization of the entire oncology sector. It demonstrates the scale of its mission and the financial risks associated with it.
Debt to book value of all companies in the market
CG Oncology is a biotech company whose research could transform cancer treatment. This chart compares its debt, taken on to fund R&D, to the total book value of the entire economy. It shows how big the company's bet on a scientific breakthrough is relative to the overall size of the stock market that finances it.
P/E of the company, segment and market as a whole
P/E - CG Oncology Inc.
This metric for CG Oncology, Inc., a biopharmaceutical company focused on cancer treatment, reflects investor expectations. For a company in clinical development and without revenue, its value is determined by the potential of its innovative therapies. The chart shows how much the market believes in the future commercial success of its drugs.
P/E of the market segment - Cancer cure
This metric represents the average valuation for the biotech sector in which CG Oncology operates. In this industry, which is full of research-stage companies, the average earnings valuation is often uninformative. However, it reflects the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
CG Oncology is a late-stage biopharmaceutical company focused on developing innovative immunotherapy for bladder cancer. The company is aiming to address a serious medical need. This risk appetite chart helps understand how investors evaluate the potential for breakthroughs in oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CG Oncology Inc.
CG Oncology is a clinical-stage biopharmaceutical company developing innovative treatments for bladder cancer. This chart reflects the high investor expectations for the success of its research. It demonstrates the market's belief that the company's drugs will become a new standard in oncology and generate significant profits.
%20P%2FE%20CG%20Oncology%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CG-Oncology-Inc.&v=1772641363957 "Chart of the company's future (projected) P/E CG Oncology Inc.")
Future (projected) P/E of the market segment - Cancer cure
CG Oncology is a late-stage clinical development biopharmaceutical company developing a new class of immunotherapeutic agents for the treatment of bladder cancer patients. This chart shows overall market sentiment regarding the biotech sector, helping to assess CG Oncology's potential relative to expectations across the oncology industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772641363986 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
CG Oncology is a biotech company developing an innovative treatment for bladder cancer using an oncolytic virus. This is a cutting-edge therapy. The company's valuation is based on expected success in clinical trials and is not tied to the overall market earnings forecasts shown in the chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641364015 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CG Oncology Inc.
CG Oncology is a late-stage clinical development biopharmaceutical company developing innovative immunotherapy for bladder cancer. Its financial performance reflects significant investments in research and preparation for commercialization. This chart shows the financial costs involved in bringing a potentially breakthrough drug to market.
Profit of companies in the market segment - Cancer cure
CG Oncology, Inc. is a late-stage clinical development biopharmaceutical company focused on developing innovative immunotherapeutic agents for the treatment of bladder cancer. This chart shows the profitability of the oncology sector. The company's research expenses impact its current overall profitability, but its potential breakthrough could become a new standard of treatment and a growth driver.
Overall market profit
CG Oncology is a clinical-stage biopharmaceutical company focused on developing treatments for bladder cancer. Its value and prospects are determined solely by research results and potential drug approvals. The dynamics in this chart reflect general market trends, while CG Oncology is pursuing its own path of scientific discovery.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CG Oncology Inc.
CG Oncology is a late-stage clinical development biopharmaceutical company focused on developing innovative immunotherapy for bladder cancer. This chart reflects analysts' future revenue expectations, which are based on a high probability of approval and commercial success for its lead drug candidate, which targets a significant market.
%20profit%20of%20the%20company%20CG%20Oncology%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CG-Oncology-Inc.&v=1772641364069 "Graph of future (projected) profit of the company CG Oncology Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
CG Oncology is a late-stage biopharmaceutical company developing innovative immunotherapy for bladder cancer. This chart shows revenue projections for the oncology sector. It reflects the high interest and anticipation for new treatments that could offer patients more effective and safer alternatives.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772641364078 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
CG Oncology is a biopharmaceutical company developing innovative immunotherapy for the treatment of bladder cancer. Funding breakthrough oncology research requires significant resources. The overall market profit forecast, reflected here, influences investor willingness to invest in high-risk biotech projects. This positive environment facilitates raising capital for CG Oncology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641364102 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CG Oncology Inc.
CG Oncology is a biopharmaceutical company developing a therapy for bladder cancer. Before commercialization, the P/S ratio is uninformative. However, once the product launches, it will become a key indicator. The chart will show the premium the market is likely to pay for the first dollars of sales, anticipating that the drug will become a standard of care.
P/S market segment - Cancer cure
CG Oncology is a late-stage biopharmaceutical company developing innovative immunotherapies for bladder cancer. Its high valuation is based on the enormous potential of its lead drug. The chart below shows how high market expectations for its therapy are compared to other oncology startups.
P/S of the market as a whole
CG Oncology is a biotech company developing innovative treatments for bladder cancer using oncolytic viruses. While revenue is not yet available, its valuation reflects the high potential of its developments. This chart, showing the valuation of companies with real revenues, emphasizes that investing in CG Oncology is a bet on a breakthrough in medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CG Oncology Inc.
CG Oncology is a biotech company developing innovative immunotherapy for bladder cancer. Its valuation is a bet on the success of its lead drug. This chart reflects investor expectations for future multibillion-dollar sales should the drug be approved, potentially changing the standard of care in its niche.
%20P%2FS%20CG%20Oncology%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CG-Oncology-Inc.&v=1772641364172 "The graph of the company's future (projected) P/S CG Oncology Inc.")
Future (projected) P/S of the market segment - Cancer cure
CG Oncology, Inc. is a late-stage biopharmaceutical company developing immunotherapy for bladder cancer. This chart shows how the market views the future commercial potential of its lead drug compared to other oncology companies. It reflects the high level of anticipation and faith in its innovative approach to fighting cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772641364189 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. Its value reflects expectations for a breakthrough in the fight against this common cancer. This chart illustrates general expectations for future revenue, and CGON demonstrates how biotech companies targeting major medical problems drive investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641364231 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CG Oncology Inc.
CG Oncology is a late-stage clinical development biotech focused on developing a new class of oncolytic immunotherapy for bladder cancer. Its revenue in this chart is likely minimal or nonexistent, as it comes not from sales but from potential partnerships. Revenue growth will begin after the drug's commercialization.
Sales of companies in the market segment - Cancer cure
CG Oncology is a late-stage biotech focused on bladder cancer. Its revenue at this stage is likely derived from licensing agreements. This chart allows investors to see the cash flows from its partners, confirming the value of its core pipeline.
Overall market sales
CG Oncology is a late-stage biopharmaceutical company focused on developing innovative treatments for bladder cancer. Its value and future revenue are entirely dependent on the success of clinical trials and subsequent regulatory approval. The macroeconomic metrics reflected in this chart are irrelevant to its core business.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CG Oncology Inc.
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. Its revenue forecast is based on expectations of clinical trial success and the future commercial launch of its drugs. This chart shows analysts' confidence in the potential of its therapy to become a new standard of care.
%20sales%20of%20the%20company%20CG%20Oncology%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CG-Oncology-Inc.&v=1772641364310 "Schedule of future (projected) sales of the company CG Oncology Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
CG Oncology is a late-stage clinical development biopharmaceutical company focused on bladder cancer. This chart displays projected revenue for the entire oncology drug segment. It provides insight into how quickly analysts expect this market to grow, which is critical to CG Oncology's future commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772641364345 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
CG Oncology is a biotech company developing innovative treatments for bladder cancer. The company's success depends on the results of clinical trials, not the current economic situation. However, the overall market situation, shown in the chart, influences investor sentiment. This positive environment facilitates raising the significant funds needed to bring the oncology drug to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641364353 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CG Oncology Inc.
CG Oncology is a biotech company developing innovative treatments for bladder cancer. The chart below reflects its current status in clinical trials. It demonstrates the company's investment in research, and its future ability to generate revenue depends entirely on the success of its developments and their regulatory approval.
Market segment marginality - Cancer cure
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. Currently, this chart is an indicator of market expectations. If its drugs are successful, profitability above the industry average will demonstrate a huge unmet need for new treatments and the company's commercial success.
Market marginality as a whole
CG Oncology, Inc. is a biotech company developing innovative treatments for bladder cancer. It is at the forefront of oncology. This chart shows average market returns, while CG Oncology operates in a sector where a scientific breakthrough can completely change the treatment paradigm and create enormous shareholder value from scratch.
Employees in the company, segment and market as a whole
Number of employees in the company CG Oncology Inc.
CG Oncology is a clinical-stage biopharmaceutical company focused on developing treatments for bladder cancer. Its team consists primarily of scientists and clinicians. A rise in this graph is a strong signal of progress in clinical trials and preparation for the potential launch of an innovative drug.
Share of the company's employees CG Oncology Inc. within the market segment - Cancer cure
CG Oncology is a late-stage biopharmaceutical company developing innovative immunotherapy for bladder cancer. This chart shows the concentration of scientific focus. It demonstrates the proportion of leading urologists and oncology immunologist-oncologists working on this specific problem that CG Oncology brings together.
Number of employees in the market segment - Cancer cure
CG Oncology, Inc. is a late-stage biopharmaceutical company developing innovative treatments for bladder cancer. This chart shows employment in the oncology sector. The growing number of scientists and clinicians in this field indicates significant progress in cancer immunotherapy, creating great hope for CG Oncology's drugs.
Number of employees in the market as a whole
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. The growth of its team of scientists and clinicians is a direct result of successful research and an influx of investment. It represents the cutting edge of medicine, where job creation directly correlates with the hope of saving lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CG Oncology Inc. (CGON)
CG Oncology is a late-stage biotech developing immunotherapy for bladder cancer. Their enormous market value is based on the high potential of a single drug. This chart is a prime example of how the market values intellectual capital in pharmaceuticals: a breakthrough technology created by a small team can be worth billions.
%20of%20the%20company%20CG%20Oncology%20Inc.%20(CGON)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CG-Oncology-Inc.-CGON&v=1772641364511 "Chart of market capitalization per employee (in thousands of dollars) of the company CG Oncology Inc. (CGON)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
CG Oncology is a late-stage biotech focused on bladder cancer. Its entire market value is based on expectations for its lead drug. This chart shows the industry average. It demonstrates the significant premium investors are placing on the company's R&D team per employee.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772641364524 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. The company's value is entirely dependent on the success of its clinical trials. This chart demonstrates the enormous expectations of investors, with each scientist and physician working at the company viewed as a key asset capable of creating a breakthrough in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641364542 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CG Oncology Inc. (CGON)
CG Oncology is a biopharmaceutical company focused on developing bladder cancer treatments using oncolytic viruses. This is cutting-edge science. At the clinical trial stage, this graph is in negative territory and shows how much the company is investing in each scientist in the hopes of creating a breakthrough therapy.
%20Chart%20CG%20Oncology%20Inc.%20(CGON)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CG-Oncology-Inc.-CGON&v=1772641364565 "Company Profit Per Employee (in thousands of dollars) Chart CG Oncology Inc. (CGON)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
CG Oncology is a clinical-stage biotech company developing "oncolytic viruses" (immunotherapy) for cancer treatment. This chart shows the benchmark for the "Oncology" biotech sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through cash on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772641364604 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
CG Oncology is a biopharmaceutical company developing oncolytic immunotherapy—a virus that specifically infects and kills cancer cells (bladder cancer). This is breakthrough R&D. This chart, showing the average dollar return per employee by market, asks the question: how does the immuno-oncology sector compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641364661 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CG Oncology Inc. (CGON)
CG Oncology is a late-stage biotech company developing cancer drugs. This graph reflects its progress toward commercialization. Until the product is approved, revenue per employee may be negligible. However, if successful, this metric will skyrocket, demonstrating the enormous value of the intellectual property being created.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CG-Oncology-Inc.-CGON&v=1772641364795 "Sales chart per company employee CG Oncology Inc. (CGON)")
Sales per employee in the market segment - Cancer cure
CG Oncology is a biopharmaceutical company developing innovative treatments for bladder cancer. The company is in active clinical trials. This chart shows the average revenue per employee in the segment, serving as a productivity benchmark for commercial companies and helping to evaluate the effectiveness of CGON's workforce within the industry context.
Sales per employee for the market as a whole
CG Oncology (CGON) is a late-stage biotech developing treatments for bladder cancer. Given the promising nature of their developments, the company is actively recruiting staff for clinical trials and commercialization preparations. While this metric doesn't yet reflect efficacy, investors are monitoring it in anticipation of FDA approval and a subsequent surge in revenue.
Short shares by company, segment and market as a whole
Shares shorted by company CG Oncology Inc. (CGON)
CG Oncology is a biotech company developing innovative bladder cancer treatments using oncolytic viruses. This is promising, but risky. This chart shows high skepticism. Bears are betting that their therapy will prove ineffective in late-stage trials or will face strong competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CG-Oncology-Inc.-CGON&v=1772641364893 "Short Shares Chart for the Company CG Oncology Inc. (CGON)")
Shares shorted by market segment - Cancer cure
CG Oncology is a late-stage biotech developing immunotherapy drugs for bladder cancer. This chart highlights the pessimism in the oncology sector. The increase in short positions in the sector may indicate that investors are concerned about the intense competition in this market or the tightening of regulations for new drugs, which poses risks for companies close to commercialization.
Shares shorted by the overall market
CG Oncology (CGON) is a late-stage biotech developing a therapy for bladder cancer. It's a niche sector. This chart measures overall market pessimism. When investors are fearful (the indicator rises), they often sell off biotechs that haven't yet turned a profit, fearing the company will need cash in a bad market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CG Oncology Inc. (CGON)
CG Oncology is a clinical-stage biotech. Its shares are highly sensitive to trial news. This CGON chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CG-Oncology-Inc.-CGON&v=1772641364931 "RSI 14 indicator chart for the company's stock CG Oncology Inc. (CGON)")
RSI 14 Market Segment - Cancer cure
CG Oncology, Inc. is a biotech company developing cancer immunotherapy drugs. Their lead candidate targets bladder cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by speculative expectations of clinical success.
RSI 14 for the overall market
CG Oncology (CGON) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CGON (CG Oncology Inc.)
CG Oncology is a biopharmaceutical company developing innovative immunotherapies for the treatment of bladder cancer. This chart shows the average analyst forecast. Their targets reflect a high assessment of the company's lead drug's potential, its chances of approval, and its commercial success in treating oncological diseases with unmet needs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CGON-CG-Oncology-Inc.&v=1772641365014 "A chart showing analyst consensus forecasts for the expected stock price. CGON (CG Oncology Inc.)")
The difference between the consensus estimate and the actual stock price CGON (CG Oncology Inc.)
CG Oncology is a clinical-stage biotech developing oncolytic viruses. This innovative therapy uses a virus specifically modified to attack and kill cancer cells, in their case, bladder cancer. This chart reflects analysts' high expectations for their clinical data. It reflects the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CGON-CG-Oncology-Inc.&v=1772641365105 "A chart showing the difference between the consensus forecast and the actual stock price. CGON (CG Oncology Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
CG Oncology is a biotech company that uses "viruses" to fight cancer (oncolytic virotherapy), specifically bladder cancer. It's a cutting-edge, but risky, approach. This chart shows analysts' overall expectations for the entire cancer treatment sector. It reflects whether experts believe this innovative therapy will be successful.
Analysts' consensus forecast for the overall market share price
CG Oncology (CGON) is a biotech company focused on developing oncolytic viruses—viruses specifically modified to infect and destroy cancer cells. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk cancer treatments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CG Oncology Inc.
CG Oncology is a late-stage biotech company focused on cancer treatment. Their lead drug is an oncolytic virus that is injected into the bladder to fight cancer. This graph represents pure R&D betting. It likely reflects investor confidence in their technology, successful clinical trial data, and the potential of their drug.
AKIMA Market Segment Index - Cancer cure
CG Oncology (CGON) is a clinical-stage biotech focused on cancer immunotherapy; the company is developing an oncolytic virus (Cretostimogene) for the treatment of bladder cancer. This summary metric evaluates R&D. The graph shows the segment average. This benchmark provides insight into how CGON's innovative (virus-versus-cancer) R&D strategy differentiates it from the average pharma company.
The AKIM Index for the overall market
CG Oncology is a clinical-stage biotech company focused on cancer immunotherapy. Its technology uses a virus to attack bladder tumors. This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop for funding such companies.
